The ALS Association
ALS Ice Bucket Challenge Progress

Our unique approach

From harnessing innovative ideas, to translating concepts to therapies, to advancing treatments to people living with ALS – The ALS Association’s collaborative and global approach to funding research continues to lead to significant discoveries by top ALS scientists around the world.


Expediting the discovery of treatments and a cure

treatments and cures graphic

With the world’s largest ALS research program, The ALS Association is active in more than 150 labs around the globe. Meet the scientists and view an interactive map to learn more about the projects that your support makes possible!

View Research We Fund

Scientific focus areas critical to ALS research


Biomarkers. Nanotechnology. Disease mechanisms. Precision medicine. Drug development and more. The ALS Association supports a wide breadth of specific fields of study that are critical to advancing ALS research.

Learn More

Championing patient care

Heart shaped graphic

People living with ALS are at the center of everything we do, and must receive the best care and support possible until there's a cure.

Learn More

Driving research progress three unique ways

Maximizing investments

We secure matching gifts to double and even triple your investment in research.

Learn More

Attracting bright young scientists

We provide fellowship grants to keep the best scientists focused on ALS throughout their careers.

Learn More

Inspiring partnerships

We drive collaboration among non-profits, academia, industry and government.

Learn More

Bringing the world's ALS scientists together

Scientific review panels


Don Cleveland, Ph.D.

University of California at San Diego, Elected Member, National Academy of Sciences

Richard G. Ellenbogen, MD, FACS

Professor, University of Washington, Seattle

Strategic meetings

Fred Gage, Ph.D.

Adler Professor, Laboratory of Genetics, The Salk Institute, La Jolla, Calif.

Global collaborations

Sabrina Paganoni, M.D.

Assistant Professor at Harvard Medical School, Cambridge, Mass.

Ammar Al-Chalabi, M.D.

Professor of Neurology and Complex Genetics, King’s College London

Merit Cudkowicz, M.D., MSc

Director of Massachusetts General Hospital (MGH) MDA ALS Clinic, Boston

Frank Walsh, Ph.D.

Founder and CEO, Ossianix Inc., University City Science Center, Philadelphia, Pa.

Shared data & samples

Jane Huggins, Ph.D.

Research Assistant Professor, University of Michigan, Ann Arbor, Mich.

See All Experts

Lawrence and Isabel Barnett Drug Development Program


Our Lawrence and Isabel Barnett Drug Development Program allows us the freedom to strategically fund preclinical projects aimed at developing therapeutics for ALS that are product-driven. It is anticipated that the agents and/or data generated from these funded projects will lead to the advancement of new therapies for ALS.

Read more

Powered by Blackbaud
nonprofit software